Profile data is unavailable for this security.
About the company
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
- Revenue in USD (TTM)7.00m
- Net income in USD-101.87m
- Incorporated2015
- Employees58.00
- LocationKezar Life Sciences Inc4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-2005United StatesUSA
- Phone+1 (650) 822-5600
- Fax+1 (302) 636-5454
- Websitehttps://kezarlifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immix Biopharma Inc | 0.00 | -15.43m | 57.28m | 14.00 | -- | 2.64 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.8235 | 0.00 | -- | -- | 0.00 | -89.54 | -- | -103.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 59.30m | 20.00 | -- | 0.6937 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 59.30m | 49.00 | -- | 3.18 | -- | 6.08 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 59.47m | 729.00 | -- | 0.4713 | -- | 0.3449 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Aligos Therapeutics Inc | 15.53m | -87.68m | 59.75m | 66.00 | -- | 0.6287 | -- | 3.85 | -1.82 | -1.82 | 0.3204 | 1.22 | 0.1041 | -- | -- | 235,287.90 | -58.80 | -51.20 | -72.71 | -59.73 | -- | -- | -564.61 | -1,399.21 | -- | -- | 0.0026 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 60.02m | 58.00 | -- | 0.3199 | -- | 8.57 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Turnstone Biologics Corp | 19.31m | -55.24m | 60.13m | 80.00 | -- | 3.90 | -- | 3.11 | -2.68 | -2.68 | 0.9103 | 0.6672 | -- | -- | -- | 241,325.00 | -- | -- | -- | -- | -- | -- | -285.92 | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Moolec Science SA | 2.65m | -52.66m | 60.79m | 45.00 | -- | 6.00 | -- | 22.98 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -19.77m | 61.26m | 13.00 | -- | 104.23 | -- | -- | -1.49 | -1.49 | 0.00 | 0.0281 | 0.00 | -- | -- | 0.00 | -201.88 | -- | -347.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -40.42m | 61.32m | 26.00 | -- | 0.4957 | -- | -- | -3.57 | -3.57 | 0.00 | 6.01 | 0.00 | -- | -- | 0.00 | -42.05 | -37.02 | -44.82 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Annovis Bio Inc | 0.00 | -56.20m | 61.33m | 6.00 | -- | -- | -- | -- | -6.12 | -6.12 | 0.00 | -0.7368 | 0.00 | -- | -- | 0.00 | -243.15 | -106.31 | -328.17 | -124.71 | -- | -- | -- | -- | -- | -4.03 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -34.36m | 61.54m | 14.00 | -- | 4.00 | -- | -- | -26.09 | -26.09 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -132.51 | -63.99 | -155.72 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Kronos Bio Inc | 6.29m | -112.67m | 61.90m | 62.00 | -- | 0.3817 | -- | 9.84 | -1.95 | -1.95 | 0.1089 | 2.70 | 0.0248 | -- | -- | 101,419.40 | -44.34 | -35.47 | -48.77 | -37.14 | -- | -- | -1,791.87 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 62.61m | 117.00 | -- | 0.2341 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Data as of May 01 2024. Currency figures normalised to Kezar Life Sciences Inc's reporting currency: US Dollar USD
45.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 31 Dec 2023 | 7.17m | 10.10% |
| Avidity Partners Management LPas of 31 Dec 2023 | 5.03m | 7.08% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.36m | 6.15% |
| Prosight Management LPas of 31 Dec 2023 | 3.37m | 4.74% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.01m | 4.25% |
| Millennium Management LLCas of 31 Dec 2023 | 2.93m | 4.13% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 2.05m | 2.89% |
| Granahan Investment Management, LLCas of 31 Dec 2023 | 1.91m | 2.69% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.35m | 1.91% |
| Two Sigma Advisers LPas of 31 Dec 2023 | 1.32m | 1.86% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
